<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8080">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858845</url>
  </required_header>
  <id_info>
    <org_study_id>641</org_study_id>
    <secondary_id>R01HL084525</secondary_id>
    <nct_id>NCT00858845</nct_id>
    <nct_alias>NCT01046344</nct_alias>
    <nct_alias>NCT01826643</nct_alias>
  </id_info>
  <brief_title>Using Clonidine to Improve Leg Weakness in People With Heart Failure</brief_title>
  <official_title>Clonidine and the Skeletal Myopathy of Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with heart failure often have weakness in their leg muscles. This study will
      determine whether the leg weakness is due to very high adrenaline levels and whether the
      medication clonidine can improve leg weakness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure is a common condition, affecting approximately 5 million people in the United
      States. People with heart failure are encouraged to exercise and lose weight. However, many
      people with heart failure develop weakness in their leg muscles, which can make exercise
      difficult. Increased sympathetic nerve activity, which involves the nerves that carry
      adrenaline, also occurs in people with heart failure. It is possible that the increased
      sympathetic nerve activity may actually cause the leg muscle weakness. Clonidine, a
      medication used to treat high blood pressure, has been found to decrease sympathetic nerve
      activity. This study will further examine the connection between leg weakness and
      sympathetic nerve activity. It will also evaluate the effectiveness of clonidine at
      decreasing leg weakness in people with heart failure. Results from this study may explain
      why some people with heart failure are unable to exercise and may help to identify ways in
      which leg strength can be increased.

      This study will enroll people with heart failure. Participants will be randomly assigned to
      wear either a clonidine patch or a placebo patch for 3 months. Participants will wear the
      patch on their upper arm, and they will replace the patch each week. At study visits at
      baseline and Month 3, participants will undergo the following procedures:

        -  Sympathetic nerve activity recording, which will record nerve activity in the lower
           leg, using small electrodes inserted through the skin

        -  Muscle biopsy, in which a small piece of muscle tissue will be obtained from
           participants' legs

        -  Heart rate and blood pressure measurements

        -  Arterial baroreceptor measurements, in which the nerves in the body that respond to
           changes in blood pressure will be examined while participants receive different
           medications to increase and decrease their blood pressure

        -  Echocardiography to obtain images of the heart

        -  Magnetic resonance scan of the leg

        -  Passive exercise procedure, in which study researchers will conduct an arm exercise
           with participants

      There will be no follow-up visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Citrate Synthase Activity</measure>
    <time_frame>Measured at Month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Citrate synthesis is an estimate of mitochondrial activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle Fiber Type</measure>
    <time_frame>Measured at Month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fibers witll be typed as I or II according to presence of myosin heavy chain</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Muscle Sympathetic Nerve Activity</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Muscle sympathetic nerve activity will be measured as bursts sympathetic nerve activity per minute.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Clonidine patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will wear a clonidine patch.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine Patch</intervention_name>
    <description>A clonidine patch (0.1 mg/week) will be worn for 3 months.</description>
    <arm_group_label>Clonidine patch</arm_group_label>
    <other_name>Catapress-TTS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart failure

        Exclusion Criteria:

          -  Currently on Coumadin therapy

          -  Experienced a heart attack in the 3 months before study entry

          -  Medically unable to receive clonidine

          -  Advanced kidney or liver disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holly R. Middlekauff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Middlekauff HR, Verity MA, Horwich TB, Fonarow GC, Hamilton MA, Shieh P. Intact skeletal muscle mitochondrial enzyme activity but diminished exercise capacity in advanced heart failure patients on optimal medical and device therapy. Clin Res Cardiol. 2013 Aug;102(8):547-54. doi: 10.1007/s00392-013-0564-3. Epub 2013 Apr 11.</citation>
    <PMID>23575739</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 4, 2013</lastchanged_date>
  <firstreceived_date>March 6, 2009</firstreceived_date>
  <firstreceived_results_date>June 19, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Holly R Middlekauff</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Leg Weakness</keyword>
  <keyword>Skeletal Myopathy</keyword>
  <keyword>Sympathetic Nerve Activity</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All heart failure patients were recruited from the Ahmanson-University of California, Los Angeles (UCLA) Cardiomyopathy Center between 2008-2011.</recruitment_details>
      <pre_assignment_details>Of 44 heart failure patients interested, 25 were ineligible (medication changes (6), “too well” with either left ventricular ejection fraction(LVEF) &gt;35% (3) or New York Heart Association (NYHA) Class I (2), transportation issues (4), morbidly obese (3), enrolled in exercise program (2), other (5)), and of the remaining 19 patients, 8 declined.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Clonidine Patch</title>
          <description>Participants will wear a clonidine patch.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient underwent heart transplant.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clonidine Patch</title>
          <description>Participants will wear a clonidine patch.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50" spread="3.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Citrate Synthase Activity</title>
        <description>Citrate synthesis is an estimate of mitochondrial activity</description>
        <time_frame>Measured at Month 3</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Clonidine Patch</title>
            <description>Participants will wear a clonidine patch.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Citrate Synthase Activity</title>
            <description>Citrate synthesis is an estimate of mitochondrial activity</description>
            <units>micromole/min/100mg wet weight</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" spread="0.09"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Fiber Type</title>
        <description>Fibers witll be typed as I or II according to presence of myosin heavy chain</description>
        <time_frame>Measured at Month 3</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Muscle Sympathetic Nerve Activity</title>
        <description>Muscle sympathetic nerve activity will be measured as bursts sympathetic nerve activity per minute.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clonidine Patch</title>
          <description>Participants will wear a clonidine patch.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a small trial, but it was not terminated early, and there were no technical issues.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Holly R. Middlekauff</name_or_title>
      <organization>University of California, Los Angeles (UCLA)</organization>
      <phone>310-206-6672</phone>
      <email>hmiddlekauff@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
